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Abstract
Background
The use of core outcome sets (COS) ensures that researchers measure and report those
outcomes that are most likely to be relevant to users of their research. Several hundred
COS projects have been systematically identified to date, but there has been no formal qual-
ity assessment of these studies. The Core Outcome Set-STAndards for Development
(COS-STAD) project aimed to identify minimum standards for the design of a COS study
agreed upon by an international group, while other specific guidance exists for the final
reporting of COS development studies (Core Outcome Set-STAndards for Reporting [COS-
STAR]).
Methods and findings
An international group of experienced COS developers, methodologists, journal editors,
potential users of COS (clinical trialists, systematic reviewers, and clinical guideline develop-
ers), and patient representatives produced the COS-STAD recommendations to help
improve the quality of COS development and support the assessment of whether a COS
had been developed using a reasonable approach. An open survey of experts generated an
initial list of items, which was refined by a 2-round Delphi survey involving nearly 250 partici-
pants representing key stakeholder groups. Participants assigned importance ratings for
each item using a 1–9 scale. Consensus that an item should be included in the set of mini-
mum standards was defined as at least 70% of the voting participants from each stakeholder
group providing a score between 7 and 9. The Delphi survey was followed by a consensus
discussion with the study management group representing multiple stakeholder groups.
COS-STAD contains 11 minimum standards that are the minimum design recommenda-
tions for all COS development projects. The recommendations focus on 3 key domains: the
scope, the stakeholders, and the consensus process.
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Conclusions
The COS-STAD project has established 11 minimum standards to be followed by COS
developers when planning their projects and by users when deciding whether a COS has
been developed using reasonable methods.
Introduction
The selection of appropriate outcomes in clinical trials and systematic reviews needs greater
attention from the scientific community, if study findings are to be useful, reliable, and rele-
vant to patients, healthcare professionals, and others making decisions regarding healthcare
provision. Core outcome sets (COS) are an agreed standard set of outcomes that should be
measured and reported, as a minimum, in all clinical trials in specific areas of health or health-
care [1]. The main rationales for COS are the need to improve comparability across similar tri-
als, reduce selective outcome reporting, and increase the relevance of results from trials and
systematic reviews.
The Core Outcome Measures in Effectiveness Trials (COMET) Initiative has systematically
identified several hundred published COS [2–4] and registered more than 150 ongoing or
planned studies in a free, publicly available, searchable database [5]. Issues to consider in COS
development have been described [1], but the key elements for good-quality COS have not pre-
viously been identified through any systematic process involving all relevant stakeholders. The
COMET systematic reviews [2–4] have identified variability in several aspects of COS develop-
ment, including the scope, the stakeholders, and the consensus process.
Defining the quality of a COS is not straightforward. In principle, a ‘good’ COS is one that
is implemented and leads to improved outcomes for patients, but this impact will be far down-
stream of the development process and cannot be assessed from information on the project
that developed the COS [6]. In this article, we present the results of a research project to iden-
tify a set of minimum standards for COS development. These standards will help COS devel-
opers to improve their methodological approach and help users to assess whether a particular
COS has been well developed.
Scope of COS-STAD recommendations
No gold standard method for the development of a COS currently exists, although empirical
evidence is starting to appear [6]. Given the number of new COS projects being registered in
the COMET database, and the growing experience of COS development, it was timely to assess
whether international agreement regarding design principles could be reached. The aim of the
COS-STAD project was to identify those aspects of COS development for which minimum
standards can be agreed upon and applied regardless of the specific consensus method chosen.
The COS-STAD recommendations relate to the development process and assume that the
need for a COS has already been established [6]. COS-STAD recommendations are relevant to
all COS, regardless of the area of healthcare and whether the COS was developed for effective-
ness trials, systematic reviews, or routine care. In parallel with the Core Outcome Set-STAn-
dards for Reporting (COS-STAR) reporting guideline [7], the COS-STAD recommendations
were developed to address the first stage of development, namely gaining agreement on what
should be measured, recognising that a COS describes what should be measured in a particular
research or practice setting, with subsequent work needed to determine how each outcome
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should be defined or measured. The distinction between COS-STAD and COS-STAR is that
COS-STAD focusses on the principles of design associated with COS development, while
COS-STAR relates to the reporting of COS development studies.
Ethical approval
Ethical approval was granted for COS-STAR under an expedited review agreement (Reference
RETH000841). Since the process for identifying and approaching participants to take part in
COS-STAD was the same as for COS-STAR, no separate research ethics approval was sought.
Informed consent was assumed if a participant responded to the surveys.
Development of the COS-STAD recommendations
Study group members (COS-STAR authors and consensus meeting participants) were invited
via an online survey to specify which aspects they considered most important when developing
a COS. Participants were provided with a copy of the COS-STAR reporting guideline items as
a framework for organizing possible suggestions. The survey question asked, ‘Please list the
“minimum standards” that you think are important when developing a COS’. Each respondent
could provide as many items as he or she wished. Responses to the survey were reviewed inde-
pendently by 2 experienced COS developers (JJK and PRW), duplicate suggestions were
removed, and the remaining responses were grouped into domains. Respondents were asked
to clarify suggestions that were unclear or ambiguous. An explanation of the process for con-
verting participant suggestions into domains and a preliminary list of items are provided in S1
Text. The preliminary list of 16 items was agreed upon after discussion with the other core
members of the COS-STAD management group (DGA, JMB, MC, and ST). These items cov-
ered 3 domains: scope (4 items), stakeholders (4 items), and the consensus process (8 items).
This preliminary list was included in a Delphi survey of 4 key stakeholder groups, details of
which are listed in Table 1. Participants were sent a personalised email outlining the project,
together with a link to the survey, a copy of the COS-STAR reporting guideline [7], and the
first update of a systematic review of COS studies [3]. All Delphi survey text was reviewed by
the COMET PoPPIE (Patient Participation, Involvement and Engagement) coordinator in
order to confirm the readability of the language prior to launching the survey.
Delphi participants rated the importance of each candidate item on a scale from 1 (not
important) to 9 (critically important). In round 1 of the Delphi study, participants could sug-
gest new items to be included in the second round but were asked not to suggest items consid-
ered good practice for research projects in general (e.g., obtaining ethical approval). In round
2, each participant who participated in round 1 was shown the number of respondents and the
distribution of scores for each item, for all stakeholder groups separately, together with their
own score from round 1. The data from the 3 COS user groups were presented separately.
Four additional items suggested in round 1 were included and scored in round 2; the full list of
additional items suggested in round 1 but not included in round 2 is given in S2 Text with rea-
sons for their noninclusion. Consensus was defined a priori as requiring at least 70% of the
voting participants from each stakeholder group to give a score between 7 and 9. COS develop-
ers (n = 103), COS users (n = 83; systematic reviewers n = 31, trialists n = 41, and clinical
guideline developers n = 11), medical journal editors (n = 36), and patient representatives
(n = 11) participated in both rounds. The Delphi process was conducted online and managed
using DelphiManager software developed by the COMET Initiative [13]. The anonymised data
from both rounds of the Delphi process, itemised by stakeholder group, are available as S1
Data.
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Eight items reached consensus for all stakeholder groups and were automatically included
in the final set of COS-STAD recommendations. The members of the COS-STAD Manage-
ment Group were provided with a summary of the results (S1 Table) and asked to indepen-
dently consider the remaining 12 items that did not reach consensus amongst all stakeholder
groups, and they then voted as to whether the item should be included or not in the final set of
standards. After the vote, 2 items supported by all COS-STAD Management Group members
were included in the final set of standards, and 6 were excluded. The decision regarding the
remaining items was made through discussion, and a further item was included, while 3 were
excluded. A summary of the voting and this process is available in S2 Table.
Testing of the application of the minimum standards to assess COS projects was done by 15
PhD candidates as part of a training event in March 2017, hosted at the University of Liverpool
in association with the European joint doctorate programme on Methods in Research on
Research [14]. Students, all of whom were independent of the COS-STAD development pro-
cess, worked in small groups to assess adherence of a published COS to the minimum stan-
dards [15]. They were also asked to comment on the content, format, and usefulness of
COS-STAD. Feedback from this exercise revealed that it would be beneficial if those appraising
COS against the standards had access to all publications relating to the COS development pro-
cess, including the protocol if available.
The COS-STAD recommendations
The 11 minimum standards presented in Table 2 are applicable to projects in which the aim is
to decide which outcomes should be included in the COS. They do not address how those out-
comes should be defined or measured, because guidance for that part of the process already
Table 1. Stakeholder groups and participants involved in the Core Outcome Set-STAndards for Development (COS-STAD) Delphi survey.
Stakeholder group Eligibility criteria Number
invited
Number responded
in round 1 (n)
Number responded in
round 2 (n, % retention)
(1) COS developers Corresponding authors of published COS projects in the COMET
database, with a request to forward the invitation to any
methodologist that participated
253 105 103 (98%)
(2) Journal editors Editors in chief of journals in which COS studies have been
published or that are involved with CROWN*, which is a group of
journals that endorse the uptake of COS [8]
131 43 36 (84%)
(3) COS users (a) Principal investigators of open phase III/IV trials, commercial
or noncommercial and registered on ClinicalTrials.gov (~10%
random sample from all ongoing registered trials listed on 16
November 2016)
857 46 41 (89%)
(b) Coordinating editors from 53 Cochrane Review Groups 76 33 31 (94%)
(c) Clinical guideline developers* (G-I-N members) [9] 156 14 11 (79%)
(4) Patient
representatives
Patient representatives from COMET workshops and the
COMET PoPPIE working group* [10]
12 12 11 (92%)
Mixed stakeholder
representatives#
Members of the OMERACT Executive Committee* (a group that
advocates the use of COS for musculoskeletal conditions) [11]
12
Mixed stakeholder
representatives#
Those that registered for the COMET VI conference in
Amsterdam in 2016 [12]
160
* Invited to participate in the study by a third party, due to these being member organisations.
# Participants were invited to select the most relevant stakeholder of the 4-stakeholder groups when participating in the Delphi tn1.
COMET, Core Outcome Measures in Effectiveness Trials; COS, core outcome set; CROWN, Core Outcomes in Women’s Health; G-I-N, Guidelines
International Network; OMERACT, Outcome Measures in Rheumatology; PoPPIE, Public and Patient Participation, Involvement and Engagement.
https://doi.org/10.1371/journal.pmed.1002447.t001
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exists [16]. The recommendations relate to 3 aspects of the COS development process: scope,
stakeholders, and the consensus process.
Domain 1: Scope. The scope should be defined in terms of the research or practice set-
tings (standard 1) in which the COS is to be applied, health conditions (standard 2), target
populations (standard 3), and interventions (standard 4). No recommendation is made about
whether the scope of a COS should be narrow or broad, but rather, the recommendation made
is that these four components should be considered and specified. For example, COS develop-
ers need to decide whether the COS is to be developed for research, routine care, or both (stan-
dard 1). The health conditions (standard 2) may be broad, e.g., all cancers, or more specific,
e.g., prostate cancer. The population covered by the COS (standard 3) might be all patients
with the condition or could be a specific subset, such as either localised or advanced prostate
cancer patients. Finally, COS developers need to consider and specify whether the COS will
apply to all interventions for the condition of interest or just specific intervention types, e.g.,
surgery, drugs, or medical devices (standard 4). Defining the scope of the COS at the outset of
the consensus process should reduce subsequent difficulties that might arise from ambiguity of
Table 2. Core Outcome Set—STAndards for Development: The COS-STAD recommendations.
Domain Standard
number
Methodology Notes
Scope
specification
1 The research or practice setting(s) in which
the COS is to be applied
COS developers should consider the details of the setting (e.g., for
application in research studies or for use in routine care) that will be
covered by the COS.
2 The health condition(s) covered by the COS COS developers should consider the details of the health conditions
(e.g., treatment of rheumatoid arthritis or screening for cancer) that will
be covered by the COS.
3 The population(s) covered by the COS COS developers should consider the details of the population (e.g.,
patients with advanced disease or children) that will be covered by the
COS.
4 The intervention(s) covered by the COS COS developers should consider the details of the interventions (e.g., all
interventions, drug therapy, or surgical interventions) that will be
covered by the COS.
Stakeholders
involved
5 Those who will use the COS in research COS developers should involve those who will do the research that will
use the COS (e.g., clinical trialists or industry).
6 Healthcare professionals with experience of
patients with the condition
COS developers should involve those healthcare professionals who
would be able to suggest important outcomes (e.g., clinical experts,
practitioners, and investigators with particular experience in the
condition).
7 Patients with the condition or their
representatives
COS developers should involve those who have experienced or who are
affected by the condition (e.g., patients, family members, and carers).
Consensus
process
8 The initial list of outcomes considered both
healthcare professionals’ and patients’ views.
COS developers should consider the views of healthcare professionals
and patients (most likely identified from literature reviews or interviews)
when generating an initial list of outcomes for inclusion in the consensus
process.
9 A scoring process and consensus definition
were described a priori.
Although different consensus methods may be employed in different
studies, to avoid any potential biases, COS developers should describe
their consensus method a priori.
10 Criteria for including/dropping/adding
outcomes were described a priori.
COS developers should also prespecify criteria for including, dropping,
or adding new outcomes to avoid potential biases.
11 Care was taken to avoid ambiguity of
language used in the list of outcomes.
COS developers should consider the language used when describing
outcomes in front of different stakeholder groups. An example of 1
approach taken is to include both lay and medical terms, with these
previously piloted with the stakeholders.
COS, core outcome set.
https://doi.org/10.1371/journal.pmed.1002447.t002
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purpose. A clear specification will also help potential users decide on the relevance of the COS
to their work.
Domain 2: Relevant stakeholders. Three stakeholder groups have been identified as the
minimum for input into the development of a COS: those who will use the COS in research
(standard 5), healthcare professionals (standard 6), and patients or their representatives (stan-
dard 7). Clinical trialists are an example of those who will use a COS in a research setting.
Healthcare professionals are those who have direct involvement with the care and manage-
ment of patients in the area for which the COS is being developed. In addition, in order for a
COS to include outcomes that are most relevant to patients and carers, the inclusion of
patients and carers in the COS development process is crucial.
Domain 3: Transparent consensus process. Transparency in the consensus process is
important in order to assess whether COS recommendations were developed in a rigorous and
unbiased way. Standards relating to the consensus process address 4 aspects. Outcomes con-
sidered during the consensus process should reflect the views from all relevant stakeholders
(standard 8). COS developers may therefore want to consider a combination of approaches for
generating the initial list of outcomes: for example, a list of outcomes from published clinical
trials may be supplemented by a review of qualitative research studies investigating patients’
opinions or information from interviews with patients. Determining the scoring system and
definition of consensus in advance (standard 9) reduces the risk of bias that could occur if the
criteria are changed after seeing the results. Consensus criteria that are too relaxed may result
in a long list of outcomes that potential users might not consider to be a core set, whilst too
stringent criteria may result in key outcomes not reaching the threshold for inclusion. In a
similar vein, the criteria for including, dropping, and adding outcomes should be defined in
advance (standard 10). The language used to describe each potential outcome for the core set
should be unambiguous (standard 11). When considering language, adequate consideration
should be given to getting this right for those involved in the consensus process as well as for
potential users, which may lead to the use of both plain language descriptions and medical
terms, with these pilot tested for understanding.
Discussion
Our intention in developing the COS-STAD recommendations is to encourage researchers to
achieve at least the minimum standards for COS development and to help users assess whether
a COS should be adopted in practice. Those looking to appraise and use published COS will
need to use their own judgement regarding the applicability of the COS (scope) for the purpose
they require. The COS-STAD recommendations are minimum standards and should not
restrict COS developers in relation to other aspects of the process. For example, developers
should include additional stakeholder groups in the development of the COS if it is felt that
they are also relevant. The minimum standards relate to the principles that should be followed
in the development of a COS regardless of the consensus method used. More information on
different methods for achieving consensus and current evidence related to specific aspects of a
consensus process for COS development can be found in the COMET Handbook [6].
Consensus was reached on 8 of the 20 candidate items at the end of the Delphi exercise.
The COS-STAD Management Group voted and discussed the results for the remaining 12
items and concluded that 2 further items should be included because the majority of stake-
holder groups agreed or were very close to agreement that the item was critically important.
The item related to including/dropping/adding outcomes was added for consistency with the
item related to the process for scoring outcomes. Defining the consensus and scoring criteria
and the criteria for including/dropping and adding outcomes in advance (standards 9 and 10,
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respectively) would promote transparency in the reporting of the methods used and help avoid
changing the criteria after the results have been analysed.
While making publicly available the protocol for a COS development study was not agreed
upon as a minimum standard, the availability of a protocol will increase the transparency of
the COS development process. Good research practice in general includes developing a proto-
col before the start of a study and making it publicly available on a suitable platform. Two of
the other items that were not included in the final set related to how the views of multiple
stakeholder groups will be taken into account in the consensus definition and how the views of
multiple stakeholder groups will be taken into account when deciding whether to include,
drop, or add outcomes during the consensus process. While these 2 items were deemed impor-
tant by some stakeholder groups in the Delphi exercise, the COS-STAD Management Group
did not include these explicitly because it was felt that they could already be covered by stan-
dards 9 and 10. Finally, some participants in round 1 of the Delphi process suggested an addi-
tional item, namely, that a systematic review should be undertaken to identify outcomes to be
included in the consensus process. This was included for scoring in round 2 of the Delphi but
only reached consensus in half of the stakeholder groups. This item was discussed by the
COS-STAD Management Group but not included because it was felt that whilst a systematic
review may be desirable, it could not yet be deemed essential in the absence of evidence that
other forms of review or gathering of the initial list of outcomes would not suffice.
COS-STAD focusses on the main design principles for COS development, while COS-
STAR [7] is exclusive to the reporting of COS studies. While COS-STAD might be used at the
beginning of a COS development project and COS-STAR at the end, synergy exists between
these 2 guidance documents. For example, there would be an expectation that important
design principles should be reported, and since part of the methodology was for COS-STAD
participants to consider the COS-STAR reporting guideline when generating the initial list of
items, we have been able to deliver a set of minimum standards that are coherent with the rele-
vant reporting guideline.
It is clear that few existing published COS would meet all 11 standards. COS methodology
and consensus methodology have developed over recent years. As an example, the involve-
ment of patients or their representatives is an area in which improvement is needed [4]. Rather
than initiating new COS studies, additional work could be undertaken to supplement existing
COS—for example, engagement with patients for those COS studies that did not originally
include patients could be undertaken to improve existing pieces of work and to then meet this
current minimum standard.
COS-STAD might be useful for users in healthcare areas in which there are several pub-
lished COS for the same condition. For example, there are at least 4 COS projects in childhood
asthma, with each using a different methodology and proposing slight variations in the core
outcomes [17–20].
Although the acceptance rate from the Delphi invitation may appear low (Table 1), contin-
ued participation in round 2 was high for all stakeholder groups, with no evidence of attrition
bias. Informed by the Delphi results, the COS-STAD Management Group decided on the final
set of minimum standards. Bringing experts together for a formal consensus meeting to dis-
cuss only a small number of items was not considered to be worthwhile, particularly consider-
ing that the expertise of the Management Group covered all stakeholder groups with the
exception of patient representatives. To address this limitation, we intend to work through the
COMET PoPPIE Group, to actively disseminate the minimum standards to patient organisa-
tions and encourage their feedback.
There is growing concern about the relevance of some COS to research in low- and middle-
income countries, since participation in COS studies in those areas has been limited. The
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location of many participants involved in COS development has primarily been the United
States, the United Kingdom, Canada, and other European countries [21]. In the COS-STAD
project, we did invite participants from global lists, but we did not collect information on the
geographical location of responders. We have no reason to think that the design principles
covered by the COS-STAD recommendations would not apply to all countries.
We welcome feedback on the COS-STAD recommendations. Future work is planned to
explore whether criteria can be developed to identify those COS that have been developed
using high-quality methods. Readers are invited to submit comments and criticisms, especially
those based on experience and research evidence, via the COMET website [22]. These will be
considered for future refinement of these recommendations.
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Efstathia Gkioni, Ketevan Glonti, Anna Koroleva, Christopher Norman, Linda Nyanchoka,
Maria Olsen, Camila Olarte Parra, Melissa Sharp, Cecilia Superchi, Van Nguyen Thu, and Vo
Tat Thang.
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